Camille Verry

Dr Verry is senior Radiation Oncologist (MD, PhD) at the University Hospital in Grenoble (France) since 2013, member of STROBE Inserm UA7 team, and associate researcher at Harvard Medical School, Boston (USA) December 2020 - August 2021 (Fulbright award ). Dr Verry is coordinator of 2 clinical trials and principal investigator of 7 clinical trials concerning radiation therapy. He is expert in prostate cancer, brachytherapy, nanoparticles, radiosensitizer, European synchrotron, and brain metastasis. His research is focused on improving the efficacy of radiation therapy for incurable tumors using synchrotron radiation and nanoparticles. His PhD results has led to a first-in-man clinical trial with the injection of a gadolinium nanoparticle (AGuIX) as a radiosensitizing agent. He first demonstrated a radiosensitizing effect in a brain tumor animal model. Then he coordinated the phase 1 study concerning patients with multiple brain metastases treated by radiotherapy and AGuIX. The first encouraging results are currently being published (Theranostics and Sciences advances) and pave the way for NanoRad2 (NCT03818386) multicenter randomized trial currently recruiting. He is also co-investigator of another first in man study concerning brain metastases treated by synchrotron stereotactic radiation at ESRF (NCT 01640509). Dr Verry is co-author of 24 articles and 3 book chapters. The first encouraging results are currently being published (Theranostics and Sciences advances) and pave the way for NanoRad2 (NCT03818386) multicenter randomized trial currently recruiting. He is also co-investigator of another first in man study concerning brain metastases treated by synchrotron stereotactic radiation at ESRF (NCT 01640509). Dr Verry is co-author of 24 articles and 3 book chapters. The first encouraging results are currently being published (Theranostics and Sciences advances) and pave the way for NanoRad2 (NCT03818386) multicenter randomized trial currently recruiting. He is also co-investigator of another first in man study concerning brain metastases treated by synchrotron stereotactic radiation at ESRF (NCT 01640509). Dr Verry is co-author of 24 articles and 3 book chapters.